Total Payments
$687.30
2023 Payments
$57.27
Companies
13
Transactions
40
Medicare Patients
1,679
Medicare Billing
$236,059
Payment Breakdown by Category
Food & Beverage$441.18 (64.2%)
Education$246.12 (35.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $441.18 | 21 | 64.2% |
| Education | $246.12 | 19 | 35.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $231.43 | 18 | $0 (2023) |
| Janssen Biotech, Inc. | $118.07 | 2 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $93.44 | 5 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $57.34 | 4 | $0 (2020) |
| Pharmacyclics LLC, An AbbVie Company | $36.89 | 2 | $0 (2021) |
| Acrotech Biopharma LLC | $25.90 | 2 | $0 (2022) |
| Myovant Sciences Inc. | $23.93 | 1 | $0 (2021) |
| GENZYME CORPORATION | $21.73 | 1 | $0 (2018) |
| AbbVie, Inc. | $20.43 | 1 | $0 (2019) |
| EMD Serono, Inc. | $16.59 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $57.27 | 3 | PFIZER INC. ($57.27) |
| 2022 | $169.50 | 15 | PFIZER INC. ($143.60) |
| 2021 | $38.01 | 2 | Myovant Sciences Inc. ($23.93) |
| 2020 | $142.93 | 4 | Janssen Biotech, Inc. ($118.07) |
| 2019 | $104.71 | 6 | Novartis Pharmaceuticals Corporation ($56.44) |
| 2018 | $128.44 | 7 | Pharmacyclics LLC, An AbbVie Company ($22.81) |
| 2017 | $46.44 | 3 | Novartis Pharmaceuticals Corporation ($16.44) |
All Payment Transactions
40 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/05/2023 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $25.00 | General |
| Category: ONCOLOGY | ||||||
| 09/05/2023 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $12.80 | General |
| Category: ONCOLOGY | ||||||
| 05/09/2023 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $19.47 | General |
| Category: ONCOLOGY | ||||||
| 10/14/2022 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $12.80 | General |
| Category: ONCOLOGY | ||||||
| 10/14/2022 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $7.98 | General |
| Category: ONCOLOGY | ||||||
| 08/29/2022 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $12.80 | General |
| Category: ONCOLOGY | ||||||
| 08/29/2022 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $7.98 | General |
| Category: ONCOLOGY | ||||||
| 08/09/2022 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $12.80 | General |
| Category: ONCOLOGY | ||||||
| 08/09/2022 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $10.54 | General |
| Category: ONCOLOGY | ||||||
| 06/03/2022 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $12.80 | General |
| Category: ONCOLOGY | ||||||
| 06/03/2022 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $9.76 | General |
| Category: ONCOLOGY | ||||||
| 04/27/2022 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $12.80 | General |
| Category: ONCOLOGY | ||||||
| 04/27/2022 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $9.76 | General |
| Category: ONCOLOGY | ||||||
| 04/22/2022 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $12.80 | General |
| Category: ONCOLOGY | ||||||
| 04/22/2022 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $7.98 | General |
| Category: ONCOLOGY | ||||||
| 04/13/2022 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $12.80 | General |
| Category: ONCOLOGY | ||||||
| 03/17/2022 | Acrotech Biopharma LLC | BELEODAQ (Drug) | Education | In-kind items and services | $13.93 | General |
| Category: ONCOLOGY | ||||||
| 01/28/2022 | Acrotech Biopharma LLC | BELEODAQ (Drug) | Education | In-kind items and services | $11.97 | General |
| Category: ONCOLOGY | ||||||
| 10/19/2021 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $14.08 | General |
| Category: ONCOLOGY | ||||||
| 03/31/2021 | Myovant Sciences Inc. | ORGOVYX (Drug) | Education | In-kind items and services | $23.93 | General |
| Category: HORMONE THERAPY | ||||||
| 03/02/2020 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $9.49 | General |
| Category: Oncology | ||||||
| 02/25/2020 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $108.58 | General |
| Category: Oncology | ||||||
| 02/19/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological), LENVIMA | Food and Beverage | In-kind items and services | $12.59 | General |
| Category: ONCOLOGY | ||||||
| 02/10/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $12.27 | General |
| Category: Oncology | ||||||
| 12/09/2019 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug), TAFINLAR | Food and Beverage | In-kind items and services | $20.74 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 6 | 365 | 642 | $104,612 | $44,638 |
| 2021 | 7 | 605 | 1,472 | $225,302 | $101,691 |
| 2020 | 9 | 709 | 1,516 | $222,778 | $89,731 |
Total Patients
1,679
Total Services
3,630
Medicare Billing
$236,059
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 200 | 306 | $46,512 | $18,467 | 39.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 40 | 71 | $15,265 | $7,181 | 47.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 35 | 90 | $15,750 | $7,065 | 44.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 40 | 122 | $14,640 | $6,748 | 46.1% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 30 | 33 | $7,425 | $3,324 | 44.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 20 | 20 | $5,020 | $1,853 | 36.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 289 | 776 | $117,952 | $52,762 | 44.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 91 | 372 | $44,640 | $20,691 | 46.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 42 | 103 | $18,025 | $8,103 | 45.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 43 | 70 | $15,050 | $8,039 | 53.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 56 | 56 | $14,056 | $5,263 | 37.4% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 47 | 49 | $11,025 | $4,863 | 44.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 37 | 46 | $4,554 | $1,971 | 43.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 254 | 656 | $99,712 | $37,077 | 37.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 108 | 430 | $51,600 | $23,792 | 46.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 51 | 78 | $13,650 | $6,379 | 46.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 125 | 177 | $17,523 | $6,077 | 34.7% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 62 | 62 | $15,562 | $5,603 | 36.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 46 | 46 | $10,350 | $4,740 | 45.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 20 | 20 | $6,500 | $3,026 | 46.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 29 | 31 | $6,665 | $2,541 | 38.1% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 14 | 16 | $1,216 | $495.78 | 40.8% |
About Dr. Nasser Janbay, M.D
Dr. Nasser Janbay, M.D is a Hematology & Oncology healthcare provider based in Oklahoma City, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/26/2005. The National Provider Identifier (NPI) number assigned to this provider is 1699768374.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nasser Janbay, M.D has received a total of $687.30 in payments from pharmaceutical and medical device companies, with $57.27 received in 2023. These payments were reported across 40 transactions from 13 companies. The most common payment nature is "Food and Beverage" ($441.18).
As a Medicare-enrolled provider, Janbay has provided services to 1,679 Medicare beneficiaries, totaling 3,630 services with total Medicare billing of $236,059. Data is available for 3 years (2020–2022), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Oklahoma City, OK
- Active Since 08/26/2005
- Last Updated 06/02/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1699768374
Products in Payments
- IBRANCE (Drug) $215.76
- DARZALEX (Biological) $108.58
- KEYTRUDA (Biological) $57.34
- XTANDI (Drug) $30.78
- BELEODAQ (Drug) $25.90
- ORGOVYX (Drug) $23.93
- Imbruvica (Drug) $22.81
- ELITEK (Drug) $21.73
- PIQRAY (Drug) $21.36
- MEKINIST (Drug) $20.74
- RYDAPT (Drug) $20.56
- Venclexta (Drug) $20.43
- Bavencio (Biological) $16.59
- AFINITOR (Drug) $16.44
- PROMACTA (Drug) $14.34
- Lenvima (Drug) $14.17
- IMBRUVICA (Drug) $14.08
- OPDIVO (Biological) $12.27
- ERLEADA (Drug) $9.49
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Oklahoma City
Robert Reynolds, Md, MD
Hematology & Oncology — Payments: $14,579
Hematology & Oncology $14,579
Philip Comp, Md, MD
Hematology & Oncology — Payments: $13,151
Hematology & Oncology $13,151
Dr. Charles Hollen, M.d, M.D
Hematology & Oncology — Payments: $12,135
Hematology & Oncology $12,135
Jennifer Holter-Chakrabarty, Md, MD
Hematology & Oncology — Payments: $11,994
Hematology & Oncology $11,994
Dr. Saadia Chohan, Md, MD
Hematology & Oncology — Payments: $11,197
Hematology & Oncology $11,197
Abby Bova, Md, MD
Hematology & Oncology — Payments: $5,791
Hematology & Oncology $5,791